Light lets one molecule switch CB1 on and CB2 off

A photoswitchable ligand for opposite control over cannabinoid receptors CB1 and CB2.

European journal of medicinal chemistry • • Highly Relevant
🤖

AI Summary

Researchers developed Azo23, a light-sensitive molecule designed to control the two main cannabinoid receptors, CB1 and CB2. Ultraviolet light changes Azo23 from its trans form to its cis form, switching how it interacts with these receptors. After irradiation, the molecule acts as a potent CB1 agonist while blocking CB2 activity as an antagonist.

The compound showed an activity shift of more than 50-fold, and molecular modeling suggested that different interactions with each receptor explain its opposing effects. This is a laboratory research tool rather than a cannabis product or treatment, but it could help scientists separate the often-overlapping roles of CB1 and CB2. In the longer term, light-controlled compounds such as Azo23 may support more precise investigation of cannabinoid signaling, although the abstract does not report testing in people or practical effects for cannabis users.

💡 Key Findings

1
Ultraviolet light converts Azo23 from its trans to cis form, changing its activity at the two cannabinoid receptors.
Moderate
55%
2
In its light-induced form, Azo23 acts as a potent CB1 agonist and a CB2 antagonist, producing an activity shift of more than 50-fold.
Moderate
55%
3
Molecular docking identified distinct receptor interactions that may explain Azo23’s opposing effects at CB1 and CB2.
Moderate
45%
4
Azo23 is presented as a new photopharmacological tool for studying the separate roles of CB1 and CB2, rather than as an established cannabis treatment.
Moderate
50%

📄 Original Abstract

Photopharmacology offers a powerful strategy for the spatiotemporal modulation of protein function with molecular precision. While all the current photoswitchable ligands developed to date act on single targets, we report Azo23, the first bifunctional photoswitchable ligand that exerts opposing efficacy modulation toward two closely related G protein-coupled receptors, cannabinoid receptors CB1 and CB2. Upon ultraviolet irradiation, Azo23 isomerizes from its trans to cis form, resulting in a potent CB1 agonist and CB2 antagonist, with a remarkable activity shift exceeding 50-fold. Molecular dockings reveal distinct receptor interactions underlying this dual behavior. Azo23 thus represents a unique photopharmacological tool for dissecting the complex and often overlapping roles of CB1 and CB2, and emerges as a promising lead compound for light-controlled modulation of cannabinoid signaling.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.